Affiliation:
1. Shanghai Institute of Technology
Abstract
Abstract
A new glucose-responsive polymer made from carbopol and 3-phenylboronic acid was developed with condensation reaction. The resulting polymer possesses a pKa of 6.86 ± 0.38 at a proper feedstock ratio of 1:2 (w/w), which approached the physiological pH. The hydrogel made of the corresponding polymer exhibited good features in response to changes of glucose concentration and solution pH value. The features were elevated owing to the addition of ammoniated ZnO nanoparticles, and be related to the structure morphology of hydrogel converted into irregular sheet along with porous structure from initial regular lamellar. Two types of microneedles containing insulin were also made and demonstrated their enough piercing abilities by mechanical compression test. Transdermal release tests of insulin in vitro displayed well responsive release performances, and then the pulsatile releases ensued since glucose concentration alternated between 400 and 100 mg/dL, indicating that the developed micronedle system can realize the controlled release of insulin, i.e. the constructed smart carbopol polymer have potential application in the field of biomedicine.
Publisher
Research Square Platform LLC
Reference33 articles.
1. Liu M, Liu SW, Wang LJ, Bai YM, Zeng XY. (2019) Burden of diabetes, hyperglycaemia in china from to 2016: Findings from the 1990 to 2016, global burden of disease study - sciencedirect. Diabetes & Metabo. 45: 286–293. https://doi.org/10.1016/j.diabet.2018.08.008
2. The artificial pancreas in 2017: The year of transition from research to clinical practice;Kovatchev B;Nat Rev Endocrinol.,2018
3. Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: A systematic review and meta-analysis of outpatient randomised controlled trials;Weisman A;Lancet Diabetes Endo.,2017
4. A porous reservoir-backed boronate gel microneedle for efficient skin penetration and sustained glucose-responsive insulin delivery;Chen S;Gels.,2022
5. On-demand transdermal insulin delivery system for type 1 diabetes therapy with no hypoglycemia risks;Fu Y;J Colloid Interf Sci.,2022